Impedimed有限公司近日宣布，其2025财年第四季度的总合同价值达到630万澳元，较去年同期大幅增长29%。这一强劲表现彰显了公司在销售和增长资本设施领域的持续扩张。与此同时，Impedimed还成功与Legacy Health签订了一份9单元的新合同，进一步巩固了业务基础并推动未来增长潜力。整体来看，这些数据突显了公司稳健的财务势头和市场竞争力。
Impedimed有限公司近日宣布，其2025财年第四季度的总合同价值达到630万澳元，较去年同期大幅增长29%。这一强劲表现彰显了公司在销售和增长资本设施领域的持续扩张。与此同时，Impedimed还成功与Legacy Health签订了一份9单元的新合同，进一步巩固了业务基础并推动未来增长潜力。整体来看，这些数据突显了公司稳健的财务势头和市场竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.